New cancer drug kinder than chemotherapy
Newer cancer treatments such as immunotherapies and targeted agents like blinatumomab promise gentler alternatives to traditional chemotherapy, but raise sharp questions about cost, access, and risk. Commenters compare U.S. and U.K. pricing, highlighting how national health systems negotiate drug costs, ration expensive therapies, and even factor patients’ dependents and expected benefit into treatment decisions. Alongside personal accounts of life-saving outcomes, the conversation touches on emerging radiation techniques (e.g., proton and “flash” therapy), the economics of drug R&D, and skepticism toward both slow incremental progress and unproven “miracle” cures.
Drug pricing, NHS, and global incentives
- Discussion centers on very high list prices for new cancer drugs (e.g., six-figure annual costs in the US) versus lower but still substantial prices in the UK.
- UK NHS is described as a near‑monopsony that negotiates hard; sticker prices are public, but real prices often involve confidential discounts.
- Some patients see per‑dose costs in the thousands of pounds and are surprised that “free at point of use” still means large taxpayer outlays.
- NICE can effectively force price cuts by refusing reimbursement if a drug isn’t cost‑effective, which posters describe as de facto price control.
- There’s debate over whether aggressive price control harms R&D and rare-disease drug development, versus US high prices cross‑subsidizing global innovation.
Blinatumomab, chemo, and immunotherapy tradeoffs
- One leukemia patient describes blinatumomab as life‑saving but initially considered riskier than chemo due to cytokine release syndrome risk and need for intensive monitoring.
- Others cite review data suggesting serious CRS is rare and often manageable, and note newer options like CAR‑T cells.
- Several point out chemo’s harsh long‑term effects and argue “kinder” immunotherapies aim to maintain efficacy with less collateral damage, though chemo remains essential for many.
Radiation, proton, and advanced physics‑based therapies
- Proton therapy is described as superior to x‑ray radiation for some deep tumors, but not a miracle: still adverse effects, planning tradeoffs, and very high facility costs.
- “Proton flash” therapy (ultra‑high dose rate) is presented as experimental; hypothesis is better sparing of healthy tissue, mechanism unclear.
- Other niche or experimental approaches mentioned include Boron Neutron Capture Therapy and antibody–drug conjugates for more localized chemo-like effects.
Ethics, triage, and valuing life
- Some UK posters claim treatment decisions may consider cost, age, prognosis, and dependents, sparking debate over whether parents of young children should be prioritized.
- Others reference economic “value of life” frameworks based on working years, while noting these don’t usually include having children.
Progress vs stagnation, and alternative ideas
- One side argues oncology is ossified, relying on “poison” chemo and achieving only small gains.
- Others, including people in the field and patients, counter that immunotherapies and better protocols have significantly improved survival and are actively reducing chemo intensity.
- Fringe or speculative ideas raised: dog dewormer fenbendazole as a cheap cancer treatment (mixed anecdotal and case‑report outcomes), dietary/overnutrition hypotheses, resonant-frequency cancer destruction; these are discussed cautiously or skeptically and remain unproven in the thread.